[DOI] [PMC free article] [PubMed] [Google Scholar] 52.Chavan R.R., Bhinge S.D., Bhutkar M.A., Randive D.S., Wadkar G.H., Todkar S.S
One Bottle
Molecular Characteristics Compound Name: 5-Amino-1MQ CAS Number: 42464-96-0 Compound Class: Quinoline derivative small molecule Form: Encapsulated research compound Purity: 99% analytical purity Unit Size: 50mg capsules (60 count) Stability Profile and Storage Recommendations Store in a cool, dry environment Protect capsules from moisture and light Avoid excessive heat exposure Maintain sealed packaging when not in use Follow standard laboratory storage practices Solubility and Preparation Considerations Capsule contents may be dissolved in compatible laboratory solvents Suitable for biochemical assay buffer systems Compatible with aqueous laboratory solutions May be used in metabolic pathway assay preparations Compatible with standard in-vitro research protocols Technical Specifications product Name 5-Amino-1MQ 50mg Capsules brand BioPeptides cas 42464-96-0 purity 99% analytical purity unit Size 50mg capsules (60 count) form Encapsulated research compound synthesis Controlled chemical synthesis analytical HPLC and purity verification molecular Structure Quinoline-based small molecule stability Stable when stored in dry conditions Analytical Validation and Quality Assurance Purity verification using analytical testing Compound identity confirmation Batch-to-batch consistency evaluation Chemical stability verification Manufacturing quality control procedures Regulatory and Compliance Statement 5-Amino-1MQ supplied by BioPeptides is intended strictly for laboratory and scientific research use only
Key highlights Tirzepatide (also known by FDA-approved brand names Mounjaro and Zepbound) is a dual receptor agonist (GLP-1/GIP) that helps reduce appetite, control blood sugar, and promote greater weight loss than single receptor GLP-1 receptor agonists, such as semaglutide
Tirzepatide suppresses appetite so dramatically that some researchers struggle to eat enough, while the fasting requirement for AOD 9604 adds an additional timing constraint
